Trial of IC351 in Female Scleroderma Patients With Raynaud's and Sexual Dysfunction

Completed · Phase 2

Conditions studied: Systemic Sclerosis

In brief

Purpose of the study is to evaluate the effectiveness and safety of a new investigational dur, IC351. Study is designed to gather information regarding the possible usefulness of IC351 as a treatment of several blood vessel features of scleroderma. This includes Raynaud phenomenon as well as the vaginal dryness and discomfort associated with scleroderma

Key facts

Study ID

NCT00707187

Run by

University of Medicine and Dentistry of New Jersey

People needed

120

Starts

2001-07-01

Expected to finish

2002-07-01

Last updated by the study team

2008-06-30

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Female with diagnosis of scleroderma
• Stable sexual relationship with male partner or be sexually active
• Raynaud phenomenon at least 6 times per week
• Willing to attempt sexual activity 1/month during study period

You may not qualify if…

• Severe internal organ problems related to scleroderma
• Other gynecologic problems
• Serious depression
• Receiving other experimental and Raynaud treatments

Where it is running

• UMDNJ — New Brunswick, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.